Indian Journal of Ophthalmology

SYMPOSIUM
Year
: 2007  |  Volume : 55  |  Issue : 6  |  Page : 413--415

Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration


Ramasamy Kim 
 Chief-Retina Vitreous Services, Aravind eye Hospital, Madurai, India

Correspondence Address:
Ramasamy Kim
Chief- Retina Vitreous Services, Aravind Eye Hospital, Madurai
India

Recent developments may provide an opportunity to improve outcome in individuals who develop neovascular age-related macular degeneration (ARMD). Several therapies have been introduced that show promise for halting the progression of this disorder. However, data from controlled clinical trials to test the relative efficacy of different management strategies across the subtypes of disease remain limited. New treatment modalities that target the neovascularization process, including leakage from choroidal neovascularization (CNV), are currently being developed. Vascular endothelial growth factor (VEGF) has been implicated as a key mediator in the pathogenesis of ARMD-related CNV. Anti-VEGF strategies show promise as potential therapeutic agents for the treatment of CNV and are currently undergoing active clinical investigation. Such strategies include anti-VEGF antibodies, anti-VEGF aptamer, gene therapy and protein kinase C inhibition. This article reviews the mechanism of action and rationale for anti-VEGF drugs in ARMD.


How to cite this article:
Kim R. Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration.Indian J Ophthalmol 2007;55:413-415


How to cite this URL:
Kim R. Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol [serial online] 2007 [cited 2020 Feb 20 ];55:413-415
Available from: http://www.ijo.in/article.asp?issn=0301-4738;year=2007;volume=55;issue=6;spage=413;epage=415;aulast=Kim;type=0